ESR1 and breast carcinoma: The development of the triphenylethylene-based drug tamoxifen as an inhibitor/modulator of ER [selective estrogen-receptor modulator (SERM)] in the 1960s marked enormous progress in the therapy of breast cancer patients, but this progress was also accompanied by the discovery of tamoxifen-resistant or -insensitive tumors[98].